target context
GHSR1a
- family
- GPCR_class_A
- UniProt
- Q92847
- lane
- metabolic
annotations pending
PRX-GHSR-001
Designed peptide for GHSR1a · · UniProt Q92847 · created 2026-05-01 21:03
proof spine
49% current public evidence completeness- 01 target GHSR1a
- 02 fold missing fold
- 03 alphafold metric missing
- 04 candidate PRX-GHSR-001
- 05 finding 0 attached
- 06 export html/json/markdown
AlphaFold context
missing
- pLDDT
- missing
- confidence
- pending
- PAE
- missing or not linked
- coverage
- missing or not linked
No pLDDT value is attached, so the pack cannot treat the fold as strong structural support.
candidate gates
Gates 3/5
gate 0
input safety
passed
gate 1
structure context
passed
gate 2
candidate quality
passed
gate 3
risk screen
passed
gate 4
translatability
pending
gate 5
export readiness
pending
risk flags
Screen context
immunogenicity score
None
hERG
False
AMES
False
CYP
False
aggregation
False
WADA
False
FTO
False
Sequence
One-letter IUPAC-20 codes for authorized research records. Public claim-graph receipts keep this sequence redacted.
PMGVYGPCLW
evidence context
0 attached findings
No evidence finding has been attached yet.
timeline
0 recorded events
No timeline event attached to this candidate yet.
provenance
rfdiffusion_proteinmpnn_boltz2
- origin
- effect_driven
- PoP shield
- green
- structure confidence
- 0.89
- predicted affinity
- -11.3
limitations
What would weaken this pack
- computational-only status
- low evidence grade
- missing linked structure
- no evidence finding attached
- research-use boundary
- sequence redacted in public surfaces
Physicochemical properties
| Length | 10 aa (short peptide) |
|---|---|
| Molecular weight | 1122.37 Da |
| Isoelectric point (pI) | 5.52 |
| Net charge at pH 7.4 | -0.47 |
| GRAVY (Kyte-Doolittle) | 0.62 hydrophobic |
| Aliphatic index | 68.0 |
| ε₂₈₀ (oxidized) | 6990 M⁻¹·cm⁻¹ |
| ε₂₈₀ (reduced) | 6990 M⁻¹·cm⁻¹ |
| A₂₈₀ per mg/mL | 6.2279 |
| Aromatic (W/Y/F) | 2 |
| Charged residues | 2 |
Recommended synthesis
Solid-phase peptide synthesis (SPPS)
Sequence is short enough for cost-effective Fmoc-SPPS on Wang or Rink-amide resin. Single-coupling for most residues; double-couple any β-branched or aromatic stretches.
Strategy: Fmoc-SPPS, standard side-chain protecting groups
Target purity: ≥ 98.0% by analytical RP-HPLC
Recommended modifications
- Head-to-tail or disulfide cyclization
GPCR-targeting short peptides usually benefit from conformational restriction; head-to-tail or i,i+4 disulfide cyclization typically improves binding and proteolytic stability.
QC release panel — required from the compounding lab
- Analytical RP-HPLC (≥ purity target, single peak ≥ 95% area)
- ESI-MS or MALDI-TOF (monoisotopic mass within ±1 Da of theoretical)
- Amino-acid composition (within ±5% of theoretical)
- Residual TFA / scavenger by ¹⁹F-NMR or ion-pair HPLC (≤ 0.05% w/w)
- Endotoxin (LAL test, ≤ 1 EU/mg recommended for cell-culture use)
- Karl-Fischer water content (≤ 5%)
Storage
Lyophilized powder, sealed under argon or nitrogen, in amber vial: −80 °C for long-term (>3 months) or −20 °C for working stock (<3 months). Avoid repeated freeze-thaw.
Reconstitution (research use only)
Reconstitute in 1% acetic acid in sterile water, then dilute into research buffer (cysteines are oxidation-prone) at 1 mg/mL working stock. Aliquot single-use volumes to minimize freeze-thaw. Use within 24 h once thawed; ≤ 30 days at +4 °C in solution.
Design notes
- Hydrophobic sequence (GRAVY > 0.5) — expect aggregation and low aqueous solubility. Add 5–10% DMSO co-solvent or consider PEGylation for solubility.
- Methionine present — degas all buffers; methionine oxidation during long-term storage is the most common purity loss.
- Odd cysteine count — disulfide topology is ambiguous. Specify intended pairing on the order form or request the lab cap with an Acm protecting group.
Cryptographic provenance
PDA envelope hash:
eb9d1888ba1cf2ce62a8beb1d2b96d91da7a71f03d9d97eefcbf01ca949a31f7
This 32-byte SHA-256 hash binds the design to the exact pipeline (RFdiffusion + ProteinMPNN + Boltz-2 versions and weight digests), biosecurity policy, and TEE attestation used at design time. A verifier recomputing the PDA with different weights diverges at the envelope-hash layer — that's the platform's tamper-evidence guarantee.
Legal & safety disclaimers
- Research use only. This document is a design specification for laboratory research. It is not a prescription, not a treatment plan, and not a recommendation for human or animal use.
- Computational prediction. The peptide and its properties are predictions from the Phase 4 design pipeline (RFdiffusion + ProteinMPNN + Boltz-2 + PoP-Shield + Clinical Claims Gate). They are not experimentally validated.
- No medical advice. Peptide RX does not provide clinical advice, dosing, protocols, stacks, or acquisition guidance. Consult a licensed researcher and your IRB / IACUC before any in vitro / in vivo work.
- Compounding lab compliance. The compounding lab is responsible for compliance with all applicable regulations in its jurisdiction (FDA Section 503A/B in the US; equivalent elsewhere).
- Not FDA approved. No peptide produced via this platform is FDA-approved or intended for use in humans.
Exported via Peptide RX research-surface · pack format v1 · research use only.